2025 Q3 -tulosraportti
30 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
148
Myynti
Määrä
9 983
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
12,1VWAP
Alin
10,25VaihtoMäärä
3,1 286 381
VWAP
Ylin
12,1Alin
10,25VaihtoMäärä
3,1 286 381
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·11 t sittenPeople have many analyses for this stock, and thanks for that!!. Now you just have to lean back and enjoy the thought of how great success it will have in the future. Drink a glass of champagne and smoke a big cigar. Happy New Year!
·5 t sittenI have leaned back so much that I almost lie on the floor over the last few weeks 😅 It will be a beer and smokes for me 😁 Happy New Year 🎇
·21 t sittenIt could hardly have been written better for my part and for you others who have curasight shares in ASK :) less of a tax hit for now, and then we otherwise look forward to the expected increases in the price in H1. My guess is that we are above 13 again in mid-January 🤷 If not, then there will be shopping, win / win 😎
·21 t sittenAs previously mentioned, I would like to share my own analysis/model of Curasight as a case. There is no doubt in my mind that this can become very, very big, and the return in relation to risk is entirely on the investors' side at the current price levels we are seeing. This naturally requires that the development of the theranostic platform proceeds as expected. It is a deep analysis built on strict rigor, facts, and strategic assumptions. There is nothing like: I believe, hope, feel, sense that etc... there are assumptions and indications based on empirical evidence and previous acquisitions in Biotech. Chat GPT Pro has been used as a tool (analytically strong, but has its limitations in other areas) The analysis is dynamic and will continuously change over time as new information becomes available. Here is part 1: https://drive.google.com/file/d/1kKpmcLhNKqFzizf7-CreqssoNzD2PQBL/view (still working on Part 2 and some appendix etc.)
·20 t sitten · MuokattuNot based on much, SweetieSpotty, but seriously - calm down. You're delivering a hobby analysis now on the back of 2-3 presentations that have been, to say the least, hyping and 6 months with +500%. We have a CEO who repeatedly comments on his own stock price and calls it cheap. A bit unprofessional honestly - and one knows now that they probably also pushed the lemon a bit too much - so they could secure financing before the end of the year and create calm for 2026. Many of us find the stock exciting - it's not just you - but I would just feel a bit sorry for these "is it now I should buy this stock" types in here, who read your post and think they'll get a price of 100 any minute now. That's simply not going to happen.·15 t sitten · MuokattuI actually meant it, believe it or not. I see no problem in allowing myself to question what someone else writes in here. Many newcomers - I would hate for them to come in and believe that this one will go to price 50 by January… I am totally pro Curas but the stock should not be hyped further for now with analyses and speculations. Now the management needs peace to embark on an exciting H1 2026 without people driving the case up to more than it can currently handle. It can go to price 13 again or to 8, but for those who believe in it long-term, it definitely doesn't matter. The price and the case are two different things right now, so people shouldn't be disappointed and feel they were promised things by an analysis they read on nordnet.
·23 t sittenShould one buy more shares now, or wait a bit?
·21 t sittenWaiting is my tip, I wouldn't be surprised if the price corrects back to the issue price around 7.98? Now the stock is overbought and has risen insanely from 2 to well over 10 in a few months on expectations. Now the company must deliver corresponding results, one will get an answer to that in 2026. Good luck to everyone holding shares
·1 päivä sittenThere have been large price fluctuations this past week, but it's on very low volume. There are 45 million shares and thus only 1% has changed hands. So there is actually no major sell-off, but just a tax-driven sale in a holiday-affected market.·23 t sittenPrecisely. Just like from the start of September to the start of November, where it went from local high 6,5 to local low almost 4. It's somewhat the same that could well happen now. Two boring months with no volume and people just have to prepare themselves for it to well dive below 10 again. Without that in itself saying anything about the case, the potential or what the price will be in summer or at the end of 2026. But I think there are quite a few who took exit at 13 and expect a smaller fall back. It rose by 500% in half a year - it's absurd to hear people write that it's foolish to take such a profit.·23 t sittenIf it does, then it will naturally go back to 13 before you know it. If we talk in 4 weeks and nothing much has really happened other than some lukewarm FPD which is already priced in, then you have your classic medtech annual cycle exactly as expected. Things are quiet and it is often seen that a group of investors come in, too late to the party, and when the lights are temporarily turned off for 6 weeks, they falter.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
30 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenPeople have many analyses for this stock, and thanks for that!!. Now you just have to lean back and enjoy the thought of how great success it will have in the future. Drink a glass of champagne and smoke a big cigar. Happy New Year!·5 t sittenI have leaned back so much that I almost lie on the floor over the last few weeks 😅 It will be a beer and smokes for me 😁 Happy New Year 🎇
- ·21 t sittenIt could hardly have been written better for my part and for you others who have curasight shares in ASK :) less of a tax hit for now, and then we otherwise look forward to the expected increases in the price in H1. My guess is that we are above 13 again in mid-January 🤷 If not, then there will be shopping, win / win 😎
- ·21 t sittenAs previously mentioned, I would like to share my own analysis/model of Curasight as a case. There is no doubt in my mind that this can become very, very big, and the return in relation to risk is entirely on the investors' side at the current price levels we are seeing. This naturally requires that the development of the theranostic platform proceeds as expected. It is a deep analysis built on strict rigor, facts, and strategic assumptions. There is nothing like: I believe, hope, feel, sense that etc... there are assumptions and indications based on empirical evidence and previous acquisitions in Biotech. Chat GPT Pro has been used as a tool (analytically strong, but has its limitations in other areas) The analysis is dynamic and will continuously change over time as new information becomes available. Here is part 1: https://drive.google.com/file/d/1kKpmcLhNKqFzizf7-CreqssoNzD2PQBL/view (still working on Part 2 and some appendix etc.)·20 t sitten · MuokattuNot based on much, SweetieSpotty, but seriously - calm down. You're delivering a hobby analysis now on the back of 2-3 presentations that have been, to say the least, hyping and 6 months with +500%. We have a CEO who repeatedly comments on his own stock price and calls it cheap. A bit unprofessional honestly - and one knows now that they probably also pushed the lemon a bit too much - so they could secure financing before the end of the year and create calm for 2026. Many of us find the stock exciting - it's not just you - but I would just feel a bit sorry for these "is it now I should buy this stock" types in here, who read your post and think they'll get a price of 100 any minute now. That's simply not going to happen.·15 t sitten · MuokattuI actually meant it, believe it or not. I see no problem in allowing myself to question what someone else writes in here. Many newcomers - I would hate for them to come in and believe that this one will go to price 50 by January… I am totally pro Curas but the stock should not be hyped further for now with analyses and speculations. Now the management needs peace to embark on an exciting H1 2026 without people driving the case up to more than it can currently handle. It can go to price 13 again or to 8, but for those who believe in it long-term, it definitely doesn't matter. The price and the case are two different things right now, so people shouldn't be disappointed and feel they were promised things by an analysis they read on nordnet.
- ·23 t sittenShould one buy more shares now, or wait a bit?·21 t sittenWaiting is my tip, I wouldn't be surprised if the price corrects back to the issue price around 7.98? Now the stock is overbought and has risen insanely from 2 to well over 10 in a few months on expectations. Now the company must deliver corresponding results, one will get an answer to that in 2026. Good luck to everyone holding shares
- ·1 päivä sittenThere have been large price fluctuations this past week, but it's on very low volume. There are 45 million shares and thus only 1% has changed hands. So there is actually no major sell-off, but just a tax-driven sale in a holiday-affected market.·23 t sittenPrecisely. Just like from the start of September to the start of November, where it went from local high 6,5 to local low almost 4. It's somewhat the same that could well happen now. Two boring months with no volume and people just have to prepare themselves for it to well dive below 10 again. Without that in itself saying anything about the case, the potential or what the price will be in summer or at the end of 2026. But I think there are quite a few who took exit at 13 and expect a smaller fall back. It rose by 500% in half a year - it's absurd to hear people write that it's foolish to take such a profit.·23 t sittenIf it does, then it will naturally go back to 13 before you know it. If we talk in 4 weeks and nothing much has really happened other than some lukewarm FPD which is already priced in, then you have your classic medtech annual cycle exactly as expected. Things are quiet and it is often seen that a group of investors come in, too late to the party, and when the lights are temporarily turned off for 6 weeks, they falter.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
148
Myynti
Määrä
9 983
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
12,1VWAP
Alin
10,25VaihtoMäärä
3,1 286 381
VWAP
Ylin
12,1Alin
10,25VaihtoMäärä
3,1 286 381
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
30 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·11 t sittenPeople have many analyses for this stock, and thanks for that!!. Now you just have to lean back and enjoy the thought of how great success it will have in the future. Drink a glass of champagne and smoke a big cigar. Happy New Year!·5 t sittenI have leaned back so much that I almost lie on the floor over the last few weeks 😅 It will be a beer and smokes for me 😁 Happy New Year 🎇
- ·21 t sittenIt could hardly have been written better for my part and for you others who have curasight shares in ASK :) less of a tax hit for now, and then we otherwise look forward to the expected increases in the price in H1. My guess is that we are above 13 again in mid-January 🤷 If not, then there will be shopping, win / win 😎
- ·21 t sittenAs previously mentioned, I would like to share my own analysis/model of Curasight as a case. There is no doubt in my mind that this can become very, very big, and the return in relation to risk is entirely on the investors' side at the current price levels we are seeing. This naturally requires that the development of the theranostic platform proceeds as expected. It is a deep analysis built on strict rigor, facts, and strategic assumptions. There is nothing like: I believe, hope, feel, sense that etc... there are assumptions and indications based on empirical evidence and previous acquisitions in Biotech. Chat GPT Pro has been used as a tool (analytically strong, but has its limitations in other areas) The analysis is dynamic and will continuously change over time as new information becomes available. Here is part 1: https://drive.google.com/file/d/1kKpmcLhNKqFzizf7-CreqssoNzD2PQBL/view (still working on Part 2 and some appendix etc.)·20 t sitten · MuokattuNot based on much, SweetieSpotty, but seriously - calm down. You're delivering a hobby analysis now on the back of 2-3 presentations that have been, to say the least, hyping and 6 months with +500%. We have a CEO who repeatedly comments on his own stock price and calls it cheap. A bit unprofessional honestly - and one knows now that they probably also pushed the lemon a bit too much - so they could secure financing before the end of the year and create calm for 2026. Many of us find the stock exciting - it's not just you - but I would just feel a bit sorry for these "is it now I should buy this stock" types in here, who read your post and think they'll get a price of 100 any minute now. That's simply not going to happen.·15 t sitten · MuokattuI actually meant it, believe it or not. I see no problem in allowing myself to question what someone else writes in here. Many newcomers - I would hate for them to come in and believe that this one will go to price 50 by January… I am totally pro Curas but the stock should not be hyped further for now with analyses and speculations. Now the management needs peace to embark on an exciting H1 2026 without people driving the case up to more than it can currently handle. It can go to price 13 again or to 8, but for those who believe in it long-term, it definitely doesn't matter. The price and the case are two different things right now, so people shouldn't be disappointed and feel they were promised things by an analysis they read on nordnet.
- ·23 t sittenShould one buy more shares now, or wait a bit?·21 t sittenWaiting is my tip, I wouldn't be surprised if the price corrects back to the issue price around 7.98? Now the stock is overbought and has risen insanely from 2 to well over 10 in a few months on expectations. Now the company must deliver corresponding results, one will get an answer to that in 2026. Good luck to everyone holding shares
- ·1 päivä sittenThere have been large price fluctuations this past week, but it's on very low volume. There are 45 million shares and thus only 1% has changed hands. So there is actually no major sell-off, but just a tax-driven sale in a holiday-affected market.·23 t sittenPrecisely. Just like from the start of September to the start of November, where it went from local high 6,5 to local low almost 4. It's somewhat the same that could well happen now. Two boring months with no volume and people just have to prepare themselves for it to well dive below 10 again. Without that in itself saying anything about the case, the potential or what the price will be in summer or at the end of 2026. But I think there are quite a few who took exit at 13 and expect a smaller fall back. It rose by 500% in half a year - it's absurd to hear people write that it's foolish to take such a profit.·23 t sittenIf it does, then it will naturally go back to 13 before you know it. If we talk in 4 weeks and nothing much has really happened other than some lukewarm FPD which is already priced in, then you have your classic medtech annual cycle exactly as expected. Things are quiet and it is often seen that a group of investors come in, too late to the party, and when the lights are temporarily turned off for 6 weeks, they falter.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
148
Myynti
Määrä
9 983
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
12,1VWAP
Alin
10,25VaihtoMäärä
3,1 286 381
VWAP
Ylin
12,1Alin
10,25VaihtoMäärä
3,1 286 381
Välittäjätilasto
Dataa ei löytynyt